Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Debecarasib · LY-3962673, LOX-32846

Small molecule · Inhibitor of KRAS G12D mutant protein (KRAS) · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer

What is Debecarasib?

Debecarasib is an orally bioavailable inhibitor that noncovalently binds the oncogenic KRAS G12D mutant protein, with higher affinity for its GDP-bound conformation. It is being studied in pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY-3962673, LOX-32846
Drug type
Small molecule
Targets
KRAS G12D mutant protein (KRAS)
Mechanism
Inhibitor of KRAS G12D mutant protein (KRAS)
Pathways
KRAS signaling, downstream survival pathways
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
VAM9GV4NRT

Conditions studied

Colorectal CancerNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Other drugs acting on KRAS

More from ELI LILLY &

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Debecarasib

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.